New approaches in the treatment of patients with locally advanced breast cancer

Abstract

The problem of breast cancer (BC) becomes more urgent every year, which is characterized by an increase in the annual morbidity with this disease and rejuvenation of this pathology. BC is a leader in the structure of morbidity, so it is a very urgent task to develop new methods of treatment of this disease. Statistical data show a steady increase in the incidence of breast cancer in the past 20 years, with no tendency to stabilization [1, 2]. During the research for an adequate analysis of the results of treatment by the technique under consideration there were formed two groups of patients. The first investigated group included 221 patients, in whom 168 patients were diagnosed HER/2-neu positive tumors in immunohistochemical conclusion and 53 patients had basal-like biological subtype of the. The control group included 64 patients of whom 45 were identified to have HER/2-neu positive and 19 basal-like subtypes of breast cancer.

The control group included 58 patients, among which HER/2-neu positive subtype was found in 45 persons and basal like subtype – in 13 persons. The average life duration of patients in test group was 3,43+0,18 years, while in control group - 1,8+0,4 years that significantly exceeds the statistical data by national and foreign authors. The indices for total 3 years survival rate of patients in test group were 59,9+4,5% and 5 years survival rate - 43,1+5,5 months.

In the control group indicators of cumulative 3- and 5-year survival rates were significantly lower - 37.8% ± 6.6 and 25.2 ± 7.0%months, respectively

The indices for total 3 years and 5 years survival rate of patients in control group were significantly lower - 58,0+6,3% and 17,9+8,4% months, accordingly.